Phase II clinical trial - Hématologie Lymphome non Hodgkinien

Hématologie Lymphome non Hodgkinien
Ouvert depuis le: 07.24.2024
Site: Saint-Cloud
Public cible
A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
Description de l'essai
This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:;Àrelapsed/refractory follicular lymphoma (FL) patients;Àrelapsed/refractory aggressive (DLBCL) lymphoma patients;Àrelapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)
Investigateur principal